REVVITY INC(RVTY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVTY REVVITY INC

已收盘 09-15 16:00:00 EDT

140.19

+11.70

+9.11%

盘后140.19

+0.000.00%

19:44 EDT

最高140.22	最低128.67	成交量369.39万
今开128.67	昨收128.49	日振幅8.99%
总市值156.73亿	流通市值142.99亿	总股本1.12亿
成交额5.12亿	换手率3.62%	流通股本1.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVTY","market":"US","secType":"STK","nameCN":"REVVITY INC","latestPrice":140.19,"timestamp":1789502400000,"preClose":128.49,"halted":0,"volume":3693895,"hourTrading":{"tag":"盘后","latestPrice":140.19,"preClose":140.19,"latestTime":"19:44 EDT","volume":116388,"amount":16316147.4349,"timestamp":1789515856805,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.09105766985757636,"floatShares":102000000,"shares":111799374,"eps":2.094156,"marketStatus":"已收盘","change":11.7,"latestTime":"09-15 16:00:00 EDT","open":128.67,"high":140.22,"low":128.67,"amount":511866280.77759993,"amplitude":0.08989,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.094156,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"listingDate":-141681600000,"exchange":"NYSE","adjPreClose":128.49,"dividendRate":0.001997,"preHourTrading":{"tag":"盘前","latestPrice":127.7,"preClose":128.49,"latestTime":"09:22 EDT","volume":10,"amount":1276.4999400000002,"timestamp":1789478536983,"change":-0.79,"changeRate":-0.006148,"amplitude":0.003891},"postHourTrading":{"tag":"盘后","latestPrice":140.19,"preClose":140.19,"latestTime":"19:44 EDT","volume":116388,"amount":16316147.4349,"timestamp":1789515856805,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.377254,"impliedVol":0.4065,"impliedVolPercentile":0.49},"requestUrl":"/m/hq/s/RVTY","defaultTab":"news","newsList":[{"id":"1137427421","title":"异动解读｜Revvity盘中上涨6.11%，收购Human Cell Design强化代谢病研发布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1137427421","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137427421?lang=zh_cn&edition=full","pubTime":"2026-09-15 22:32","pubTimestamp":1789482779,"startTime":"0","endTime":"0","summary":"9月15日，Revvity盘中上涨6.11%，报136.345美元/股，成交额5045.61万美元。消息面上，Revvity近日宣布收购法国生物技术公司Human Cell Design，该公司专注于糖尿病、肥胖等代谢疾病的人体细胞模型开发。收购完成后，HCD的人胰腺β细胞模型将纳入Revvity生命科学产品线，提升其在GLP-1及其他代谢疾病疗法的药物发现与筛选能力，并拓展再生医学、细胞疗法领域的应用空间。交易预计第四季度完成，财务细节未披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Revvity大涨，收购HCD强化代谢病布局","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558747","title":"Revvity（RVTY）收购Human Cell Design 强化代谢病药物研发能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558747","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666558747?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:02","pubTimestamp":1788951731,"startTime":"0","endTime":"0","summary":"金吾财讯 | Revvity（RVTY）宣布收购总部位于法国的生物技术公司Human Cell Design，该公司专注开发糖尿病、肥胖等代谢疾病相关人体细胞模型。本次交易财务细节未对外披露，交易预计2026年第四季度完成，尚需通过监管审批及满足常规交割条件。收购完成后，Human Cell Design的人胰腺β细胞模型将纳入Revvity生命科学产品线，提升其在GLP-1及其他代谢疾病疗法的药物发现与筛选实力。同时，被收购技术还将拓展Revvity在再生医学、细胞疗法领域的应用空间。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305852","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2V16.EUR","RVTY","IE00BN0W2T93.GBP","BK4588","IBBJ","IE00B64QTZ34.USD","BK4585","IE00BLDYK493.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122428751","title":"Revvity拟收购Human Cell Design，以推进代谢疾病药物研发的人源细胞模型","url":"https://stock-news.laohu8.com/highlight/detail?id=1122428751","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122428751?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:03","pubTimestamp":1788948192,"startTime":"0","endTime":"0","summary":"Revvity（REVVITY INC）宣布，计划收购Human Cell Design公司。此举旨在推动用于代谢疾病药物发现的人源相关细胞模型向前发展。通过这次并购，Revvity期望进一步强化其在生命科学与诊断领域的布局，特别是在药物研发链条中的关键环节——细胞模型的建立与应用方面，为代谢疾病治疗方案的探索提供更具生理相关性的工具和支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B64QTZ34.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","RVTY","IE00BLDYK493.USD","BK4585","BK4588","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169146866","title":"异动解读｜REVVITY INC盘中上涨5.16%，Q2业绩大超预期叠加行业板块强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1169146866","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169146866?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:39","pubTimestamp":1787161150,"startTime":"0","endTime":"0","summary":"8月20日，REVVITY INC盘中上涨5.16%，报119.615美元/股，成交额9836万美元。消息面上，公司此前发布的Q2财报大幅超预期，调整后每股收益1.41美元，超市场预期15.57%；营收7.30亿美元，同样高于预期。同时公司上调全年指引，预计调整后EPS为5.30-5.40美元，高于市场预估的5.24美元。此外，Evercore ISI将目标价上调至126美元，维持跑赢大盘评级。当日生命科学工具和服务板块整体走强，Illumina涨8.02%、Repligen涨6.0%、丹纳赫涨5.58%，板块共振进一步推升股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186850769","title":"异动解读 | Revvity（RVTY）盘中大跌5.01%，生命科学业务疲软及Signal软件骤降引担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1186850769","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186850769?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:45","pubTimestamp":1785851110,"startTime":"0","endTime":"0","summary":"REVVITY INC（RVTY）今日盘中大跌5.01%，引发市场关注。消息面上，公司于盘前公布了2026年第二季度财报。尽管整体业绩超出市场预期——调整后每股收益达1.41美元，营收为7.30亿美元，且公司上调了全年业绩指引，但生命科学业务的表现令投资者感到担忧。二季度生命科学业务实现营收3.59亿美元，形式有机营收同比下滑3%。更值得关注的是，Revvity高管在财报电话会议上披露，生命科学部门业绩下滑的关键因素在于旗下Signal软件业务因合同签订时点的影响，营收大幅萎缩约20%。这一负面细节似乎盖过了诊断业务强劲增长及整体业绩超预期的利好，导致投资者情绪转向悲观，股价承压下行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188156495","title":"Revvity高管：生命科学部门业绩下滑，主因是Signal软件业务因合同时机问题骤降约20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188156495","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188156495?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:03","pubTimestamp":1785845029,"startTime":"0","endTime":"0","summary":"Revvity高层指出，生命科学部门的下滑背后，其实隐藏着一个关键推手——公司旗下的Signal软件业务因合同签订时点的影响，营收大幅萎缩了大约20%。这一披露引发了市场对其短期业绩波动的更多关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","RVTY","BK4121","IE00BLDYK493.USD","BK4588","BK4585","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64QTZ34.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132560511","title":"Revvity高管表示，鉴于诊断趋势，公司对下半年“更为乐观”","url":"https://stock-news.laohu8.com/highlight/detail?id=1132560511","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132560511?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:52","pubTimestamp":1785844328,"startTime":"0","endTime":"0","summary":"Revvity（REVVITY INC）的一位高管近日透露，鉴于当前的诊断行业趋势，公司如今对下半年“更为乐观”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BK4585","IE00B64QTZ34.USD","IE00BLDYK493.USD","IE00BN0W2T93.GBP","BK4121","IE00BN0W2W23.USD","RVTY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165982616","title":"Revvity高管：生物技术客户需求回暖，AI相关订单助力增长——电话会议透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1165982616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165982616?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:42","pubTimestamp":1785843733,"startTime":"0","endTime":"0","summary":"Revvity公司高管在电话会议上表示，当前生物技术客户的需求正逐步改善。这一积极态势背后，一个不容忽视的推动力来自数量日益增长的人工智能相关订单。换句话说，AI技术的渗透与应用，正为公司打开新的增长通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY","BK4585","IE00BLDYK493.USD","IE00BN0W2T93.GBP","BK4588","IE00B64QTZ34.USD","IE00BN0W2V16.EUR","BK4121","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191080431","title":"财报前瞻｜REVVITY INC本季度营收预计小幅下滑，机构普遍偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1191080431","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191080431?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:44","pubTimestamp":1785206662,"startTime":"0","endTime":"0","summary":"REVVITY INC将于2026年08月04日美股盘前发布最新季度财报，市场预计营收与利润结构分化，生命科学与诊断业务分部表现成为关注焦点。市场一致预期本季度REVVITY INC营收为7.09亿美元，同比下降0.20%；调整后每股收益为1.22美元，同比上升7.26%；息税前利润预计为1.91亿美元，同比上升2.09%。REVVITY INC上一季度营收为7.11亿美元，同比增长6.97%，毛利率为54.51%，归属于母公司净利润为4,071.80万美元，净利率为5.73%，调整后每股收益为1.06美元，同比增长4.95%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜REVVITY INC本季度营收预计小幅下滑，机构普遍偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143206979","title":"一周美股牛榜 | Bio-Techne上周飙涨逾22%，艾伯维公司劲升逾17%，联合大陆航空涨超15%，康宁涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143206979","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143206979?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:18","pubTimestamp":1782699520,"startTime":"0","endTime":"0","summary":"默克提出每股73美元的收购要约后，Bio-Techne股价本周上涨22.5%，较该公司周三收盘价溢价24%。艾伯维斥资109亿美元收购Apogee，强化免疫学领域战略艾伯维股价本周上涨17%。联合大陆航空股价上涨，油价下跌和分析师看涨情绪提振航空股本周，联合大陆航空股价上涨15%。为了进一步提升股东价值，康宁董事会宣布派发每股0.28美元的季度股息。股息将于9月29日支付给截至8月31日登记在册的股东。","market":"us","thumbnail":"https://static.tigerbbs.com/98882962e3042a24d8295da8457c9db5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/98882962e3042a24d8295da8457c9db5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IQV","ABBV","GLWG","UAL","INCY","GLW","TECH","RVTY","CRL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1157892163","title":"REVVITY INC获FDA批准总睾酮测定试剂，提供全面自动化睾酮检测方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1157892163","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157892163?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:05","pubTimestamp":1778673929,"startTime":"0","endTime":"0","summary":"REVVITY INC宣布，其总睾酮测定试剂已获得美国食品药品监督管理局（FDA）的批准。这一进展使得该公司能够提供一套全面的自动化睾酮检测解决方案，旨在提升临床实验室的检测效率与准确性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4121","IE00BN0W2W23.USD","RVTY","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148774755","title":"异动解读 | 第一季度利润超预期叠加战略业务调整，REVVITY INC盘中大涨6.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148774755","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148774755?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:36","pubTimestamp":1777988207,"startTime":"0","endTime":"0","summary":"REVVITY INC今日盘中大涨6.24%，引起了市场的广泛关注。同时，公司宣布已决定剥离其中国免疫诊断业务，此举被分析师认为在战略上是正确的，预计将提升公司有机增长。尽管公司因剥离中国业务而下调了全年营收与利润指引，但市场更关注其核心业务的盈利能力和战略聚焦。公司预计业务将从第一季度到第二季度迎来季节性回升，且第三季度利润率有望攀升至约29%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180703095","title":"Revvity高管称一季度至二季度将现季节性增长 预计三季度利润率将升至约29%——电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1180703095","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180703095?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:33","pubTimestamp":1777984382,"startTime":"0","endTime":"0","summary":"在最新电话会议中，Revvity公司高管透露，从第一季度到第二季度，公司业务预计将迎来季节性回升。此外，管理层预计，第三季度的利润率有望攀升至约29%的水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","RVTY","BK4585","BK4588","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107549957","title":"REVVITY INC高管透露：制药与学术客户贡献自2023年第二季度以来首次正向增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1107549957","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107549957?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:48","pubTimestamp":1777981736,"startTime":"0","endTime":"0","summary":"在最新电话会议中，REVVITY INC管理层指出，公司从制药领域及学术机构客户获得的业务出现显著回暖。这是自2023年第二季度以来，相关客户群体首次实现正向增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BK4121","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4585","BK4588","RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119437712","title":"Revvity高管称公司预计2026年前在华生命科学业务将持续甚至加速发展——电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1119437712","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119437712?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:41","pubTimestamp":1777981277,"startTime":"0","endTime":"0","summary":"Revvity公司高管在电话会议中表示，预计直至2026年，其在中国市场的生命科学业务表现将保持延续态势，甚至有望实现进一步加速。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2V16.EUR","RVTY","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130436153","title":"REVVITY INC签署意向书剥离中国免疫诊断业务 最终协议预计2026年第二季度达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1130436153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130436153?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:03","pubTimestamp":1777975392,"startTime":"0","endTime":"0","summary":"REVVITY INC（股票代码：RVTY）近日宣布已就剥离其中国免疫诊断业务签署意向书。这项战略性举措标志着公司正优化其诊断业务组合，将资源集中于核心增长领域。\n根据公司披露的时间表，双方预计将在2026年第二季度完成最终协议的签署。该交易将遵循标准的监管审批程序，具体交易条款尚未对外披露。\n此次业务剥离符合REVVITY INC全球战略调整方向，旨在提升运营效率并强化市场竞争力。中国市场免疫诊断业务的剥离将为公司带来更灵活的资源调配空间，同时为相关业务寻找更专业的发展平台。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","BK4588","IE00BN0W2V16.EUR","BK4121","RVTY","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183347107","title":"财报前瞻 ｜REVVITY INC本季度营收预计小幅增长，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1183347107","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183347107?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:00","pubTimestamp":1777345233,"startTime":"0","endTime":"0","summary":"REVVITY INC将于2026年05月05日发布最新季度财报，市场聚焦营收恢复与盈利质量的边际变化及诊断与生命科学双主业的结构优化进展。市场一致预期显示，本季度REVVITY INC营收预计为7.03亿美元，同比增6.37%；调整后每股收益预计为1.02美元，同比增7.06%；EBIT预计为1.63亿美元，同比降2.74%。多家机构在最近六个月内对REVVITY INC的观点偏正面，主线为营收恢复与盈利质量稳中有进、诊断与生命科学结构均衡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜REVVITY INC本季度营收预计小幅增长，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508800145","title":"Keybanc：维持Revvity(RVTY.US)评级，由增持调整至增持评级, 目标价由132.00美元调整至145.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508800145","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508800145?lang=zh_cn&edition=full","pubTime":"2025-02-03 21:51","pubTimestamp":1738590713,"startTime":"0","endTime":"0","summary":"Keybanc：维持Revvity(RVTY.US)评级，由增持调整至增持评级, 目标价由132.00美元调整至145.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/03215147941462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508748131","title":"Revvity, Inc.2024财年实现净利润2.83亿美元，同比增加57.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508748131","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508748131?lang=zh_cn&edition=full","pubTime":"2025-02-03 00:00","pubTimestamp":1738512034,"startTime":"0","endTime":"0","summary":"2月3日，Revvity, Inc.公布财报，公告显示公司2024财年净利润为2.83亿美元，同比增加57.22%；其中营业收入为27.55亿美元，同比增加0.15%，每股基本收益为--。从资产负债表来看，Revvity, Inc.总负债47.26亿美元，其中短期债务242000.00美元，资产负债比为2.63，流动比率为3.60。机构评级：截至2025年2月3日，当前有17家机构对Revvity, Inc.目标价做出预测，其中目标均价为134.41美元，其中最低目标价为102.00美元，最高目标价为155.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203000037abc01292&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203000037abc01292&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114824764","title":"异动解读 | Revvity 2024年Q4财报佳绩 盘前大涨6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114824764","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114824764?lang=zh_cn&edition=full","pubTime":"2025-01-31 21:02","pubTimestamp":1738328545,"startTime":"0","endTime":"0","summary":"今日盘前,Revvity Inc. (NYSE:RVTY)股价大涨6.03%,报收33.85美元。大涨的主要原因是公司公布的2024年第四季度财报超出市场预期。\n\nRevvity公司在财报中公布,2024年第四季度调整后每股收益1.42美元,高于分析师预期的1.37美元,同比增长13.6%;季度销售额达到7.29亿美元,也略高于预期的7.28亿美元,同比增长4.81%。优异的财报数据一定程度上反映了公司良好的发展态势和盈利能力。\n\n财报公布后,投资者对Revvity的未来增长前景抱有较高期待,从而推动了股价的大幅上涨。但需要关注的是,公司能否在未来持续保持高速增长,仍有待进一步观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revvity.com","stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":0.0997},{"period":"3month","weight":0.2694},{"period":"6month","weight":0.5129},{"period":"1year","weight":0.5505},{"period":"ytd","weight":0.3281}],"compareEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0199},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.1504},{"period":"1year","weight":0.1574},{"period":"ytd","weight":0.1158}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revvity, Inc.在1947年于马萨诸塞州成立。该公司是健康科学解决方案、技术、专业知识和服务的领先供应商，提供从发现到开发、从诊断到治愈的完整工作流程。Revvity正在彻底改变医疗保健领域的可能性，在转化多组学技术、生物标志物识别、成像、预测、筛查、检测和诊断、信息学等方面拥有专门的重点领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.028629},{"month":2,"riseRate":0.630435,"avgChangeRate":0.005389},{"month":3,"riseRate":0.434783,"avgChangeRate":-0.009865},{"month":4,"riseRate":0.446809,"avgChangeRate":-0.003599},{"month":5,"riseRate":0.659574,"avgChangeRate":0.025792},{"month":6,"riseRate":0.425532,"avgChangeRate":0.006077},{"month":7,"riseRate":0.574468,"avgChangeRate":0.007101},{"month":8,"riseRate":0.531915,"avgChangeRate":0.009446},{"month":9,"riseRate":0.446809,"avgChangeRate":0.000121},{"month":10,"riseRate":0.586957,"avgChangeRate":0.014619},{"month":11,"riseRate":0.673913,"avgChangeRate":0.025718},{"month":12,"riseRate":0.586957,"avgChangeRate":0.022842}],"exchange":"NYSE","name":"REVVITY INC","nameEN":"REVVITY INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"REVVITY INC(RVTY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供REVVITY INC(RVTY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"REVVITY INC,RVTY,REVVITY INC股票,REVVITY INC股票老虎,REVVITY INC股票老虎国际,REVVITY INC行情,REVVITY INC股票行情,REVVITY INC股价,REVVITY INC股市,REVVITY INC股票价格,REVVITY INC股票交易,REVVITY INC股票购买,REVVITY INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"REVVITY INC(RVTY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供REVVITY INC(RVTY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}